Print this page    •   Back to Web version of article

The Body Covers: The XIII International AIDS Conference
Switching Protease Inhibitor to Nevirapine Leads to Reversal of Hyperlipidemia and Lipodystrophy

Coverage provided by Alvan Fisher, M.D.

July 12, 2000


Cotton from Boehringer Ingelheim in the UK did a meta-analysis of six published studies in which the protease inhibitor (PI) component of HAART was switched to nevirapine. Overall 307 patients were enrolled in the studies. There was general consensus in terms of response of serum cholesterol and triglycerides. Total cholesterol fell from a mean of 231 to 210 at 6 months; triglycerides fell from a mean of 295 to 231 at 6 months. In half of the studies, mean cholesterol and mean triglycerides fell to below 200 by 6 months. No significant changes in blood glucose at baseline or after the switch. Three of the five studies reported improvement in body shape. Meanwhile viral suppression was generally maintained.



This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.

You can find this article online by typing the following address into your Web browser:
http://www.thebody.com/content/art16123.html

Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.